arXiv subjects

Hammed A. Olayinka

Publications and source records attributed to Hammed A. Olayinka.

2 recordsLinked to original sources

arXiv2026

A Network-Structured Bayesian Hierarchical Model for Sparse Mutation-Drug Response Associations: Application to Cancer Pharmacogenomics

We develop a network-structured Bayesian hierarchical model for sparse association mapping between genomic alterations and quantitative treatment-response phenotypes. The framework combines a Gaussian Markov random field prior that borrows strength across pathway-connected genes, a global-local horseshoe prior inducing sparsity, and a conjugate Gibbs sampler requiring no Metropolis-Hastings steps. Though broadly applicable to high-dimensional settings with known predictor networks, we validate it using cancer cell-line drug-sensitivity data. Applied to GDSC2 ($N=951$ cell lines, $G=219$ driver genes, $D=295$ drugs), the model identifies 126 gene-drug associations (0.195\% of 64{,}605 pairs), concentrated in EZH2 (45 drugs, all sensitivity-direction, mean effect $-0.911$ $\ln$IC50) and KMT2D (36 drugs, all sensitivity-direction, mean effect $-0.496$ $\ln$IC50). These markers show external support in an independent PRISM screen (1{,}518 compounds), with KMT2D achieving complete directional replication (36/36) and EZH2 partial replication (8/12). Five-fold cross-validated predictive log-likelihood confirms each prior layer's value: the full model outperforms the no-network ablation by $+3{,}109$ log-units per fold and the no-horseshoe ablation by $+14{,}039$ log-units, consistently across folds. Simulations under three scenarios show the full model achieves the highest precision and lowest false-discovery rate throughout, while the network prior improves sensitivity recovery under network-structured signal. A tissue-stratified extension identifies coherent subgroup refinements, including lung-specific EGFR-inhibitor sensitivity and skin-specific BRAF-Dabrafenib sensitivity. These results show the framework identifies sparse, interpretable, externally supported drug-sensitivity markers while enabling principled investigation of tissue-specific departures from shared effects.

stat.AP↗

arXiv2026

HB-PVI: A Hierarchical Bayesian Personalization and Value-of-Information Framework for Complex Activity Recognition

Personalization can improve activity-recognition performance, but participant-specific gains are heterogeneous, and every additional calibration label has an acquisition cost. This study presents HB-PVI, a hierarchical Bayesian personalization and value-of-information framework jointly modeling participant heterogeneity, the benefit and harm of four personalization mechanisms, and the economic value of an additional label, for the 47-participant MUSIC-CAR complex-activity cohort. A leakage-safe, leave-one-participant-out evaluation combines a sequential-Monte-Carlo participant-effect updater with a Student-$t$ hierarchical gain model and a one-step expected-value-of-sample-information (EVSI) stopping rule. Adapter personalization produced small positive mean F1 gains, growing from 0.00099 at one label to 0.00198 at ten, while adapter-plus-head and prototype-residual personalization were negative on average. Under the primary practical-benefit threshold ($Δ_{\min}=0.01$) and cost setting, one-step EVSI was zero at every decision state, so the policy purchased no labels and retained population inference for all 47 participants, matching always-stop exactly (region-of-practical-equivalence probability $=1$). Relative to fixed ten-shot adapter personalization, this reduced labeling by 100\% while keeping the posterior mean F1 loss at 0.00217 (95\% credible interval, 0.00048 to 0.00389), with posterior probability 0.9992 of remaining below the 0.005 tolerance. HB-PVI was utility-optimal in 199 of 216 cost-threshold settings and in every setting at or above the primary label cost. These results argue for a population-first deployment policy whenever personalization gains are small relative to labeling, computation, and harm costs, and show that value-of-information reasoning, not raw predictive accuracy, should drive personalization decisions in health-sensing applications.

cs.LG↗